CA
NZ
UK
AU
IND
US
…
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | -0.84M | -15.58M | -32.39M | -31.90M | -6.68M |
| Net income | -0.37M | -15.49M | -32.18M | -22.94M | -6.53M |
| Selling general administrative | 7.77M | 8.47M | 13.41M | 7.43M | 4.24M |
| Selling and marketing expenses | - | 8.47M | - | 0.26M | - |
| Gross profit | 14.99M | -0.66M | -0.67M | -9.98M | -1.27M |
| Reconciled depreciation | - | 0.66M | 0.66M | 0.76M | 1.28M |
| Ebit | -1.13M | -26.64M | -32.45M | -31.86M | -5.79M |
| Ebitda | -0.12M | -25.65M | -31.45M | -30.25M | -4.51M |
| Depreciation and amortization | 1.01M | 0.99M | 1.00M | 1.61M | 1.28M |
| Operating income | -1.13M | -26.79M | -33.09M | -31.02M | -8.96M |
| Other operating expenses | 16.78M | 17.89M | 33.09M | 39.80M | 12.94M |
| Interest expense | - | - | 0.03M | 0.03M | 1.08M |
| Tax provision | - | -0.09M | -0.14M | -0.13M | -0.14M |
| Interest income | - | 0.22M | 0.32M | 0.01M | 0.00M |
| Net interest income | - | 0.22M | 0.32M | -0.02M | -1.08M |
| Income tax expense | -0.47M | -0.09M | -0.21M | -0.28M | -0.14M |
| Total revenue | 15.65M | 0.00M | 0.00M | 0.38M | 0.93M |
| Total operating expenses | 16.12M | 17.89M | 33.09M | 23.74M | 11.25M |
| Cost of revenue | 0.66M | 0.66M | 0.67M | 16.00M | 1.69M |
| Total other income expense net | 0.29M | 2.31M | 0.70M | -0.89M | 2.28M |
| Net income from continuing ops | - | -15.49M | -21.38M | -14.97M | -6.53M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 43.44M | 27.65M | 19.39M | 65.30M | 40.77M |
| Intangible assets | 7.30M | 5.47M | 4.08M | 9.84M | 7.47M |
| Other current assets | 1.26M | 0.46M | 0.53M | 1.46M | 1.63M |
| Total liab | 14.57M | 10.16M | 4.74M | 8.40M | 5.01M |
| Total stockholder equity | 28.87M | 17.49M | 14.65M | 56.91M | 35.76M |
| Other current liab | 4.43M | 1.43M | 2.89M | 1.64M | 0.87M |
| Common stock | 0.00M | 0.00M | - | 217.67M | 142.90M |
| Capital stock | - | 0.00M | 0.00M | 149.75M | 142.90M |
| Retained earnings | -270.98M | -177.98M | -108.16M | -173.29M | -115.74M |
| Good will | 13.13M | 8.69M | 5.79M | 12.87M | 9.32M |
| Other assets | - | - | - | 0.00M | 0.00M |
| Cash | 21.59M | 12.61M | 8.06M | 33.56M | 21.41M |
| Total current liabilities | 6.41M | 3.83M | 4.12M | 3.36M | 1.77M |
| Net debt | -21.37M | -12.34M | -7.80M | -32.87M | -20.76M |
| Short term debt | 0.23M | 0.16M | 0.27M | 0.16M | 0.13M |
| Short long term debt | - | 0.03M | 0.03M | - | - |
| Short long term debt total | 0.23M | 0.27M | 0.58M | 0.69M | 0.65M |
| Other stockholder equity | 304.18M | 198.48M | 119.61M | 0.00M | 0.00M |
| Total current assets | 22.85M | 13.19M | 8.87M | 41.81M | 23.24M |
| Long term investments | - | - | - | - | 0.12M |
| Short term investments | - | - | - | - | 0.33M |
| Net receivables | 0.01M | 0.13M | 0.28M | 6.78M | 0.19M |
| Inventory | - | - | - | 0.00M | 0.00M |
| Accounts payable | 1.75M | 2.24M | 0.96M | 1.56M | 0.77M |
| Accumulated other comprehensive income | -4.32M | -3.01M | 3.20M | 12.52M | 8.60M |
| Non currrent assets other | - | -0.00M | 0.00M | 0.12M | -0.03M |
| Non current assets total | 20.59M | 14.46M | 10.52M | 23.50M | 17.53M |
| Capital lease obligations | - | 0.24M | 0.35M | 0.48M | 0.65M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | - | - | 0.32M | 0.43M | -0.06M |
| Total cashflows from investing activities | - | - | 0.32M | 0.62M | -0.06M |
| Net borrowings | - | - | -0.11M | -0.12M | -8.92M |
| Total cash from financing activities | 1528.28M | 15.11M | 5.81M | 26.99M | 23.71M |
| Net income | -369.63M | -15.49M | -14.38M | -21.76M | -6.53M |
| Change in cash | 1601.76M | 0.50M | -15.02M | 5.06M | 17.97M |
| Begin period cash flow | 12686.93M | 12.18M | 23.08M | 28.50M | 3.44M |
| End period cash flow | 14288.69M | 12.69M | 8.06M | 33.56M | 21.41M |
| Total cash from operating activities | 77.23M | -14.68M | -9.85M | -21.75M | -5.66M |
| Issuance of capital stock | - | 10.11M | 3.86M | 22.63M | 32.94M |
| Depreciation | 662.89M | 0.66M | 0.45M | 1.11M | 1.28M |
| Other cashflows from investing activities | - | - | 0.32M | 0.19M | 0.03M |
| Change to inventory | - | - | - | 0.00M | 0.00M |
| Change to account receivables | 0.11M | 0.30M | 2.78M | -5.83M | 1.52M |
| Sale purchase of stock | - | - | - | - | -0.42M |
| Other cashflows from financing activities | 1526.75M | 5.00M | 5.79M | -5.72M | -0.31M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | -0.50M | 1.46M | 3.08M | -5.60M | 1.23M |
| Stock based compensation | 163.77M | 0.81M | 1.35M | 2.83M | 0.98M |
| Other non cash items | 89.12M | -2.12M | 1.01M | 1.67M | -2.62M |
| Free cash flow | 77.23M | -14.68M | -9.85M | -21.75M | -5.67M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NEUP Neuphoria Therapeutics Inc |
-0.01 0.33% |
2.98 | - | - | 1.70 | 0.69 | 0.22 | -0.06 |
| NVO Novo Nordisk A/S |
1.99 4.95% |
42.18 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.28 3.44% |
549.04 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-41.91 4.31% |
931.45 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Spyridon Papapetropoulos M.D., Ph.D. | Interim CEO & Executive Director | 1973 |
| Mr. Timothy M. Cunningham CPA, M.B.A. | Fractional CFO | 1962 |
| Dr. Julie Kerner Ph.D. | Senior Vice President of Business Operations | NA |
| Mr. Adrian Hinton BEC, F.C.A. | Financial Controller | 1952 |
| Mr. Rajeev Chandra B.Com., C.A., M.B.A. | Company Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+2.10%
Communication Services
+1.48%
Consumer Cyclical
+2.12%
Consumer Defensive
+1.59%
Energy
-2.52%
Financial Services
+1.11%
Financials
-6.05%
Healthcare
+2.12%
Industrials
-0.12%
Real Estate
+1.25%
Technology
-0.07%
Utilities
+0.57%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...